Sinovac Biotech

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ampio, Sinovac, Lottery.com, and NIO and Encourages Investors to Contact the Firm

Retrieved on: 
星期二, 九月 27, 2022

On this news, the Companys share price fell $0.09, or 26%, to close at $0.25 per share on April 21, 2022.

Key Points: 
  • On this news, the Companys share price fell $0.09, or 26%, to close at $0.25 per share on April 21, 2022.
  • On this news, the Companys share price fell $0.04, or 10%, to close at $0.18 per share on May 18, 2022.
  • On this news, Ampios stock fell $0.06, or 37.5%, to close at $0.10 per share on August 3, 2022, thereby injuring investors.
  • For more information on the NIO class action go to: https://bespc.com/cases/NIO
    About Bragar Eagel & Squire, P.C.

ROSEN, A LEADING LAW FIRM, Encourages Sinovac Biotech Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers – SVA

Retrieved on: 
星期六, 九月 24, 2022

WHAT TO DO NEXT: To join the Sinovac class action, go to https://rosenlegal.com/submit-form/?case_id=8179 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Sinovac class action, go to https://rosenlegal.com/submit-form/?case_id=8179 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Co-Dx, Ampio, Sinovac, and Lottery.com and Encourages Investors to Contact the Firm

Retrieved on: 
星期四, 九月 22, 2022

Beginning in 2010 until approximately March 2022, Ampio conducted numerous clinical trials and analyses to determine Ampions efficacy.

Key Points: 
  • Beginning in 2010 until approximately March 2022, Ampio conducted numerous clinical trials and analyses to determine Ampions efficacy.
  • On this news, Ampios stock fell $0.06, or 37.5%, to close at $0.10 per share on August 3, 2022, thereby injuring investors.
  • For more information on the Ampio class action go to: https://bespc.com/cases/AMPE
    Since January 2016, competing sets of shareholders have been vying for control of Sinovac.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

LFST, UBER & SVA Class Actions: Bronstein, Gewirtz & Grossman, LLC, A Top Class Action Firm, Reminds Investors to Contact the Firm and Actively Participate

Retrieved on: 
星期二, 九月 20, 2022

NEW YORK, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies.

Key Points: 
  • NEW YORK, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies.
  • You can review a copy of the Complaints by visiting the links belowor you may contact Peretz Bronstein, Esq.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at212-697-6484.
  • Class Period: LifeStance Health common stock issued in connection with LifeStance Healths June 10, 2021 initial public stock offering (the IPO).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MINISO, Co-Dx, Ampio, and Sinovac and Encourages Investors to Contact the Firm

Retrieved on: 
星期六, 九月 17, 2022

As of July 27, 2022, MINISO ADSs closed at $5.66 per ADS, representing more than a 70% decline from the $20.00 IPO price.

Key Points: 
  • As of July 27, 2022, MINISO ADSs closed at $5.66 per ADS, representing more than a 70% decline from the $20.00 IPO price.
  • For more information on the Ampio class action go to: https://bespc.com/cases/AMPE
    Since January 2016, competing sets of shareholders have been vying for control of Sinovac.
  • For more information on the Sinovac class action go to: https://bespc.com/cases/SVA
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

ROSEN, A TOP RANKED INVESTOR COUNSEL, Encourages Sinovac Biotech Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers – SVA

Retrieved on: 
星期五, 九月 16, 2022

WHAT TO DO NEXT: To join the Sinovac class action, go to https://rosenlegal.com/submit-form/?case_id=8179 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Sinovac class action, go to https://rosenlegal.com/submit-form/?case_id=8179 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Co-Dx, Ampio, Sinovac, and Lottery.com and Encourages Investors to Contact the Firm

Retrieved on: 
星期一, 九月 12, 2022

Beginning in 2010 until approximately March 2022, Ampio conducted numerous clinical trials and analyses to determine Ampions efficacy.

Key Points: 
  • Beginning in 2010 until approximately March 2022, Ampio conducted numerous clinical trials and analyses to determine Ampions efficacy.
  • On this news, Ampios stock fell $0.06, or 37.5%, to close at $0.10 per share on August 3, 2022, thereby injuring investors.
  • For more information on the Ampio class action go to: https://bespc.com/cases/AMPE
    Since January 2016, competing sets of shareholders have been vying for control of Sinovac.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

ROSEN, A TOP RANKED FIRM, Encourages Sinovac Biotech Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers – SVA

Retrieved on: 
星期六, 九月 10, 2022

WHAT TO DO NEXT: To join the Sinovac class action, go to https://rosenlegal.com/submit-form/?case_id=8179 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Sinovac class action, go to https://rosenlegal.com/submit-form/?case_id=8179 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile

Retrieved on: 
星期二, 九月 6, 2022

In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited.

Key Points: 
  • In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited.
  • Mr. Weidong Yin, the Chairman, President, and CEO of SINOVAC said, SINOVAC has made great progress collaborating with global partners in the development and manufacturing of the COVID-19 vaccine.
  • Its COVID-19 vaccine, CoronaVac, has been approved for use in more than 60 countries and regions worldwide.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sinovac Biotech Ltd. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers – SVA

Retrieved on: 
星期一, 九月 5, 2022

WHAT TO DO NEXT: To join the Sinovac class action, go to https://rosenlegal.com/submit-form/?case_id=8179 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Sinovac class action, go to https://rosenlegal.com/submit-form/?case_id=8179 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.